Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036572 (seizures)
 80,221 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The use of disclosing media has been recommended to enhance the fit of castings. This study evaluated the film thickness of four disclosing media: (1) disclosing wax, (2) Net spray, (3) G-C Check Fit material, and (4) Extrude polyvinylsiloxane (low viscosity) impression material. ADA Specification No. 8 for zinc phosphate cement gives a maximum film thickness for the cement that was used as the control for these four media. The results demonstrated that the film thicknesses of all four disclosing media were less than the 25 microns maximum allowed for zinc phosphate cement.
 ...
PMID:Film thickness of four disclosing media. 207 35

Twelve parallel, open, uncontrolled therapeutic studies on 3-fluoro-6-(4-methyl-piperazinyl)- 11H -dibenz[b,e]azepine ( fluperlapine , NB-106 689) were performed as a multicenter trial using standardized protocol/case report forms and inclusion and global assessment criteria. 66% of 104 medium to severe acute or relapsed schizophrenic patients showed a very good or good overall benefit (responder rate 80%) with 200-400 mg fluperlapine daily, median 300; 20-1200 mg; 6 weeks. Ratings ( FSCL -NL = (Fischer Symptom Check List Neuroleptics, BPRS = Brief Psychiatric Rating Scale, FSUCL = Fischer Somatic Symptoms and Untoward Effects Check List) showed a quick onset of action (25% improvement in 5 days) and a very good improvement of all important and secondary single symptoms or symptom groups. FSCL -NL and BPRS were highly correlated (R = 0.87). Tolerability was very good or good in 88% of patients (very good in 65%, poor or bad in 12%), mild to moderate fatigue being the most prominent untoward effect (means 25% of patients, max. 31 per control) followed by dizziness, tremor, dry mouth (10%). No drug-induced Parkinsonism was seen. No recurrent or relevant abnormalities in relation to fluperlapine were observed in safety data (circulation, blood, kidney or liver function). Several times paroxysmal dysrhythmias/sharp waves were seen in the EEG, and in our studies 2 patients experienced epileptiform seizures of short duration after overdosage. In one patient showing a granulocytopenia before starting fluperlapine , an agranulocytosis was seen, which normalized quickly after stopping fluperlapine .
 ...
PMID:Fluperlapine in 104 schizophrenic patients. Open multicenter trial. 614 28

Ten healthy volunteers (six males; four females) completed this double-blind, crossover design study of vigabatrin vs placebo. Subjects were tested on four occasions; at the baselines of the placebo and the vigabatrin phase, and two weeks thereafter. At time of testing, the dose of vigabatrin was 2 g daily. Changes in cognition were assessed using the Sternberg, the PASAT, the Stroop, and Critical Fusion Flicker tests. Mood was assessed with the Mood Adjective Check List, the Beck Depression Inventory, and the Irritability, Depression and Anxiety scales. We found one drug, and one placebo, related significant difference on a measure of cognition.
Seizure 1996 Sep
PMID:The effects of vigabatrin on attention, concentration and mood: an investigation in healthy volunteers. 890 22

This study aimed to determine whether sodium valproate (VPA) improves cognitive performance and behaviour in children with learning and behavioural problems associated with electrographic epileptiform discharges but without clinical seizures. A randomized, double-blind, single-crossover trial was carried out with VPA or placebo on eight participants with different learning and behaviour problems. Participants also underwent neuropsychological testing under video EEG and the parent and teacher Behaviour Check List (CBCL; Achenbach 1991a, b) during each treatment phase. Clinically none of the children improved on VPA. On formal testing children were more distractable, had increased delay in response time, and showed lower memory scores while on VPA. In addition, parents reported higher internalizing scores on the CBCL while children were on VPA. Our data do not support the use of VPA in similar patients.
 ...
PMID:Can sodium valproate improve learning in children with epileptiform bursts but without clinical seizures? 1110 47

To explore whether attention, memory, and behavior would be more affected in children with frontal lobe epilepsy than in children with other types of epilepsy, we compared 16 children with frontal lobe epilepsy (FLE), 8 with temporal lobe epilepsy (TLE), and 8 with generalized absence (GEA) seizures on the Performance Speed (PS) and Freedom of Distraction (FD) indices of the WISC-III, the Continuous Performance Test (CPT), the California Verbal Learning Test (CVLT), and Rey-Osterrieth Complex Figure (ROCF). Parents completed Achenbach's Child Behavior Check List. Children with FLE scored significantly lower than the other two groups on the PS and CPT. On the CVLT they made more intrusion errors and were more prone to interference. Furthermore, they had more difficulties copying and recalling the ROCF. Behavior profiles revealed greater attention problems in this group. This may put children with FLE at greater risk of developing school problems than children with TLE and GEA.
 ...
PMID:Attention, memory, and behavioral adjustment in children with frontal lobe epilepsy. 1452 95

The subjective well-being of people with epilepsy has been studied extensively, but only sparingly in Norway. In 2005, members of the Norwegian Epilepsy Association responded to a short version of the Hopkins Symptom Check List ("psychological distress") and to a version of the Self-Anchoring Striving Scale, also termed the Cantril Ladder ("life satisfaction"). In this article, the relationships between responses to the two questionnaires (the two outcome variables) and seizure frequency, medication side effects, comorbidity, and surgery, as well as demographic variables such as age, sex, marital status, occupational status, education, and place of residence, are addressed. The analyses demonstrate clear effects of seizure frequency (P<0.001) and medication side effects (P<0.001) on both outcome variables. People with no comorbidity (no additional diagnoses) reported less psychological distress (P<0.001) and greater satisfaction with life (P<0.05) than those who reported additional diagnoses. The factor having the strongest impact on the psychological well-being of these people was medication side effects.
 ...
PMID:Psychological well-being of people with epilepsy in Norway. 1782 27

The consequences of febrile seizures (FSs) in infants are still a matter of debate. It is important to develop non-invasive tools to determine markers of brain function that could have predictive value for the outcome of FSs infants.Pattern visual evoked potentials (pVEPs) were recorded in 18 FS infants (mean age of seizure 15.97 months). Spectral density and coherence analyses were performed in infants evaluated at 1.1 month (n = 4), 5.75 months (n = 4) or 30.33 months (n = 6) following a prolonged FS and compared to age-matched healthy controls. The impact of severity of seizures was assessed by comparing the children who had prolonged FSs to 4 infants that had experienced a simple FS. Cognitive tests (Bayley, Stanford-Binet) were administered at the time of testing in FS and control children. Behavioural measures (Achenbach Child Behavior Check List) were administered two years after the FS. pVEP responses and coherence measures failed to yield significant differences between the FS groups and healthy controls. However, spectral density measures showed a significant increase in delta band activity in both FS groups and a reduced high frequency density only in the prolonged FS groups that was seen up to 39 months post-seizure. Behavioural and cognitive measures revealed cognitive development within average, but lower attentional capacities in the FS infants. The persistent changes in spectral density patterns seen in children with prolonged FS may reflect seizure induced alterations in the developing brain or a result of a complex mode of inheritance. Further studies are needed to determine whether these observations can be used as a marker to predict the vulnerability of the child in developing behavioral deficits or epilepsy.
 ...
PMID:Altered EEG spectral activity and attentional behavioral deficits following prolonged febrile seizures: a pilot study. 1928 93

Supernumerary marker chromosomes (SMC) originating from chromosome 15 are the most common SMCs. They encompass clinically irrelevant SMC(15)s containing only heterochromatin and 15p material, and clinically relevant SMC(15)s that consist of both eu- and heterochromatic 15q material. On the basis of size, the clinically relevant SMC(15)s can be subdivided into type A, "large" asymmetric and type B, "small" symmetric SMC(15)s. Type B SMC(15)s contain the triplicated 15pter to BP3 (located at 26.5 Mb) region, while type A SMC(15)s consist of 15pter --> BP4(28.5 Mb)::BP5(30.5 Mb) --> 15pter. In this study, the clinical and molecular features of 18 patients with A and B SMC(15)s and two patients with a partial trisomy 15q were reviewed. Questionnaires (including Child Behavior Check Lists) were used to assess behavior and developmental features in more detail. The marker size and parental origin were determined by multiplex ligation-dependent probe amplification (MLPA). Based on the MLPA results, the majority of patients (14/18) had type A SMC(15)s. The phenotype observed did not show significant differences between types A and B SMC(15)s. A high prevalence of autistic-like behavior, attention problems, aggressive behavior, anxiety, and sleeping problems was reported. Motor and speech development varied extensively among the patients. An association was found between positive seizure history and degree of intellectual disability.
 ...
PMID:Phenotypic spectrum of 20 novel patients with molecularly defined supernumerary marker chromosomes 15 and a review of the literature. 2068 90